Venous Leg Ulcers - Pipeline Insight, 2024

This “Venous Leg Ulcers - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Venous Leg Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Venous Leg Ulcers Understanding

Venous Leg Ulcers: Overview

Venous leg ulcers (VLUs) are defined as open lesions between the knee and ankle joint that occur in the presence of venous disease. They are the most common cause of leg ulcers, accounting for 60-80% of them. The prevalence of VLUs is between 0.18% and 1%. Over the age of 65, the prevalence increases to 4%. On an average 33-60% of these ulcers persist for more than 6 weeks and are therefore referred to as chronic VLUs. These ulcers represent the most advanced form of chronic venous disorders like varicose veins and lipodermatosclerosis. Risk factors for development of VLUs include older age, female sex, obesity, trauma, and immobility, congenital absence of veins, deep vein thrombosis (DVT), phlebitis, and factor V Leiden mutation. On physical examination, venous ulcers are generally irregular, shallow, and located over bony prominences. Granulation tissue and fibrin are typically present in the ulcer base. Associated findings include lower extremity varicosities, edema, venous dermatitis, and lipodermatosclerosis. Venous ulcers are usually recurrent, and an open ulcer can persist for weeks to many years. Severe complications include cellulitis, osteomyelitis, and malignant change. Poor prognostic factors include large ulcer size and prolonged duration. Evidence-based treatment options for venous ulcers include leg elevation, compression therapy, dressings, pentoxifylline, and aspirin therapy. Surgical management may be considered for ulcers that are large in size, of prolonged duration, or refractory to conservative measures.

Venous Leg Ulcers - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Venous Leg Ulcers pipeline landscape is provided which includes the disease overview and Venous Leg Ulcers treatment guidelines. The assessment part of the report embraces, in depth Venous Leg Ulcers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Venous Leg Ulcers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

In April 2022, Mediwound announced that EscharEx was featured in an oral presentation entitled: “Introduction to EscharEx: An Innovative Enzymatic Solution for the Debridement of Hard to Heal Wounds.” They key opinion leaders covered the efficacy and safety data from the Company’s two well controlled clinical studies in patients with venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).

Venous Leg Ulcers Emerging Drugs Chapters

This segment of the Venous Leg Ulcers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Venous Leg Ulcers Emerging Drugs

ENERGI-F703: Energenesis Biomedical ENERGI-F703 is a gel for external use accelerating healing of diabetes-caused wounds, mainly by activating AMPK inside cells to boost the density of ATP, energy molecules, in tissues near the wounds. Cellular and animal tests show that the application of ENERGI-F703 can produce the following effects: (1) reducing inflammation of endothelial cells of blood vessels; (2) accelerating the fibrosis of fibroblasts in the skin of wounds and increasing the deposition of collagen and the formation of granulation tissues; (3) speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. Via the utilization of diabetic model mouse, it's proven that the application of ENERGI-F703 gel on wounds can accelerate healing of wounds. The company has initiated a Phase II, multi-centered study to evaluate the efficacy and safety of ENERGI-F703 GEL in subjects who are = 20 years old with venous legulcer.

EscharEx: Medi WoundEscharEx is a bioactive therapy for debridement of chronic and other hard-to-heal wounds is a product candidate in advanced stages of development. EscharEx, a concentrate of proteolytic enzymes enriched in bromelain, is an easy to use product candidate, for topical daily applications, which is designed for the outpatient setting in accordance with the current treatment workflow and reimbursement programs. EscharEx has demonstrated in two phase II studies safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, with only a few daily applications. As a rapid and effective debridement agent, EscharEx is complementary to the large number of existing advanced wound healing therapies, which require a clean wound bed in order to heal the wound. It is being developed for debridement of chronic and other hard-to-heal wounds, in order to fulfill an unmet medical need for a non-surgical rapid and effective debridementmean.

Venous Leg Ulcers: Therapeutic Assessment

This segment of the report provides insights about the different Venous Leg Ulcers drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Venous Leg Ulcers

There are approx. 7+ key companies which are developing the therapies for Venous Leg Ulcers. The companies which have their Venous Leg Ulcers drug candidates in the most advanced stage, i.e. phase II include, Energenesis Biomedical

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Venous Leg Ulcers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Venous Leg Ulcers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Venous Leg Ulcers therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Venous Leg Ulcers drugs.

Venous Leg Ulcers Report Insights

• Venous Leg Ulcers Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Venous Leg Ulcers Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Venous Leg Ulcers drugs?
• How many Venous Leg Ulcers drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Venous Leg Ulcers?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Venous Leg Ulcers therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Venous Leg Ulcers and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Reponex Pharmaceuticals
• Energenesis Biomedical
• MediWound
• Solascure limited
• TR Therapeutics
• Promore Pharma AB
• Nova LeadPharma
• RHEACELL

Key Products

• rhGM-CSF
• ENERGI-F703
• EscharEx
• Aurase® Wound Gel
• TR 987
• Ropocamptide
• NLP328
• APZ 2

This product will be delivered within 2 business days.